Island Pharmaceuticals Limited (ASX: ILA) is advancing its antiviral strategy through the clinical development of Galidesivir, a broad-spectrum antiviral targeting high-consequence viral threats, including Marburg and Ebola. The program is positioned within a global biosecurity and public health framework, with regulatory engagement centred on the United States Food and Drug Administration (FDA) and potential inclusion in government stockpiles.